Life Sciences Tools and Services
Company Overview of Chromocell Corporation
Chromocell Corporation, a life sciences company, discovers and develops flavors and functional ingredients, and therapeutics based on Chromovert technology. Its Chromovert technology enables the company to use naturally occurring systems that mimic human biology as a part of its discovery platform to provide practical solutions to problems in food and pharmaceuticals. The company specializes in molecular and cell biology, assay development, screening, and medicinal chemistry areas. It also focuses on identifying new drugs/therapeutic compounds for pain relief, anxiety treatment, and treatment of respiratory disorders. In addition, Chromocell Corporation develops flavor ingredients and natura...
685 U.S. Highway One
North Brunswick, NJ 08902
Founded in 2002
Key Executives for Chromocell Corporation
Head of Business Development and Associate Director
Senior Vice President of Flavors and Natural Products
Vice President of Legal Affairs and Corporate Development
Compensation as of Fiscal Year 2016.
Chromocell Corporation Key Developments
Chromocell Corporation Appoints Heikki Mansikka as Vice-President, Clinical Development
May 8 17
Chromocell Corporation announced the appointment of Heikki Mansikka, M.D., Ph.D. as Vice-President, Clinical Development. Dr. Mansikka will be principally responsible for guiding clinical development of the Company's investigational therapeutics to treat neuropathic and other pain conditions. Dr. Mansikka will report to Dr. Kenneth Kashkin, Chromocell's Chief Operating Officer. Dr. Mansikka brings significant and relevant experience to Chromocell, having served as medical director at AbbVie across multiple therapeutic areas, including pain management. In his role at AbbVie, Dr. Mansikka provided strategic oversight for multiple preclinical-stage, small molecule compounds across the spectrum of pain management. This work enabled the advancement of multiple candidates into clinical testing. Dr. Mansikka also led cross-functional development, evaluation, and clinical validation of various translational tools supporting the Company's pain portfolio. Dr. Mansikka was also responsible for leading clinical development of multiple assets targeting immune mediated inflammatory diseases. Before his tenure at AbbVie, Dr. Mansikka held positions of increasing responsibility at several biopharmaceutical companies, including Pfizer, Mundipharma Research Limited, and Grnenthal. In these roles, he made impactful contributions across many functions, including clinical research, regulatory and commercial, spanning multiple therapeutic areas. Dr. Mansikka has experience from all phases of drug development from translational medicine up to Phase III leading clinical development program through approval.
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Oct 13 16
Chromocell Corporation and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the development program of the drug candidate CC8464/ASP1807, for the management of neuropathic pain associated with idiopathic small fiber neuropathy (iSFN). In 2015, Chromocell and Astellas entered into a license and collaboration agreement for the development and commercialization of CC8464/ASP1807 for the management of neuropathic and other pain indications. Chromocell submitted the IND for CC8464/ASP1807 in July, 2016, and recently dosed the first subject in a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the oral formulation of CC8464/ASP1807. The FDA's Fast Track program is intended to help ensure that therapies intended for serious or life threatening conditions that address unmet medical needs are approved and available to patients as soon as it can be concluded that the therapies' benefits justify their risks. Features of Fast Track designation include actions that expedite development and review including frequent interactions with the FDA Division responsible for review.
Chromocell Announces Extension of Collaboration with The Coca-Cola Company
Jul 26 16
Chromocell Corporation announced that the Chromocell and The Coca-Cola Company have agreed to continue their long-term collaboration in the flavors and sweeteners area by entering into a new multi-year research and development agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|